The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH).
 
Guoliang Shao
No Relationships to Disclose
 
Yuxian Bai
No Relationships to Disclose
 
Xiaoming Chen
No Relationships to Disclose
 
Shanzhi Gu
No Relationships to Disclose
 
Kangsheng Gu
No Relationships to Disclose
 
Xianglin Yuan
No Relationships to Disclose
 
Ryan C Widau
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Wanli Zhang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Qiang Zhang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Shukui Qin
No Relationships to Disclose